PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chronic Cough

$Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough$

Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough

September 9, 2020

$Merck&Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough$

Merck&Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough

March 18, 2020

Merck Reports the US FDA

Merck Reports the US FDA's Acceptance of NDA for Review of Gefapixant to Treat Refractory or Unexplained Chronic Cough

March 2, 2021

$Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough$

Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough

September 9, 2020

$Merck&Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough$

Merck&Co. Reports Results of Gefapixant (MK-7264) in Two P-III Studies for Refractory or Unexplained Chronic Cough

March 18, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us